The U.S. Patent and Trademark Office has invalidated three broad patents for human embryonic stem cells that have been blamed for slowing research in the highly visible field of regenerative medicine.The office ruled the discovery of embryonic stem cells from primates â?? including humans â?? was not worthy of patent protection because scientists had used similar methods to isolate embryonic stem cells from mice and other mammals, and described the cells’ potential for producing medical therapies.
Office of Strategic Communication